Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass - PubMed (original) (raw)

Clinical Trial

Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass

Carel W le Roux et al. Ann Surg. 2007 Nov.

Abstract

Objective: To evaluate the physiologic importance of the satiety gut hormones.

Background: Controversy surrounds the physiologic role of gut hormones in the control of appetite. Bariatric surgery remains the most effective treatment option for obesity, and gut hormones are implicated in the reduction of appetite and weight after Roux-en-Y gastric bypass.

Methods: We correlated peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) changes within the first week after gastric bypass with changes in appetite. We also evaluated the gut hormone responses of patients with good or poor weight loss after gastric bypass. Finally, we inhibited the gut hormone responses in gastric bypass patients and then evaluated appetite and food intake.

Results: Postprandial PYY and GLP-1 profiles start rising as early as 2 days after gastric bypass (P < 0.05). Changes in appetite are evident within days after gastric bypass surgery (P < 0.05), and unlike other operations, the reduced appetite continues. However, in patients with poor weight loss after gastric bypass associated with increased appetite, the postprandial PYY and GLP-1 responses are attenuated compared with patients with good weight loss (P < 0.05). Inhibiting gut hormone responses, including PYY and GLP-1 after gastric bypass, results in return of appetite and increased food intake (P < 0.05).

Conclusion: The attenuated appetite after gastric bypass is associated with elevated PYY and GLP-1 concentrations, and appetite returns when the release of gut hormones is inhibited. The results suggest a role for gut hormones in the mechanism of weight loss after gastric bypass and may have implications for the treatment of obesity.

PubMed Disclaimer

Similar articles

• Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
  Svane MS, Jørgensen NB, Bojsen-Møller KN, Dirksen C, Nielsen S, Kristiansen VB, Toräng S, Wewer Albrechtsen NJ, Rehfeld JF, Hartmann B, Madsbad S, Holst JJ. Svane MS, et al. Int J Obes (Lond). 2016 Nov;40(11):1699-1706. doi: 10.1038/ijo.2016.121. Epub 2016 Aug 30. Int J Obes (Lond). 2016. PMID: 27434221 Clinical Trial.
• Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review.
  Beckman LM, Beckman TR, Earthman CP. Beckman LM, et al. J Am Diet Assoc. 2010 Apr;110(4):571-84. doi: 10.1016/j.jada.2009.12.023. J Am Diet Assoc. 2010. PMID: 20338283 Free PMC article. Review.
• Preoperative assessment of gut hormones does not correlate to weight loss after Roux-en-Y gastric bypass surgery.
  Werling M, Fändriks L, Vincent RP, Cross GF, le Roux CW, Olbers T. Werling M, et al. Surg Obes Relat Dis. 2014 Sep-Oct;10(5):822-8. doi: 10.1016/j.soard.2014.04.018. Epub 2014 Apr 29. Surg Obes Relat Dis. 2014. PMID: 25282191
• The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study.
  Pournaras DJ, Osborne A, Hawkins SC, Mahon D, Ghatei MA, Bloom SR, Welbourn R, le Roux CW. Pournaras DJ, et al. Obes Surg. 2010 Jan;20(1):56-60. doi: 10.1007/s11695-009-9989-1. Epub 2009 Oct 14. Obes Surg. 2010. PMID: 19826888
• Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.
  Bojsen-Møller KN. Bojsen-Møller KN. Dan Med J. 2015 Apr;62(4):B5057. Dan Med J. 2015. PMID: 25872541 Review.

Cited by

• Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes.
  Neff KJ, Olbers T, le Roux CW. Neff KJ, et al. BMC Med. 2013 Jan 10;11:8. doi: 10.1186/1741-7015-11-8. BMC Med. 2013. PMID: 23302153 Free PMC article. Review.
• The gut sensor as regulator of body weight.
  Reinehr T, Roth CL. Reinehr T, et al. Endocrine. 2015 May;49(1):35-50. doi: 10.1007/s12020-014-0518-1. Epub 2014 Dec 30. Endocrine. 2015. PMID: 25548085 Review.
• Gut Microbiome and Obesity: A Plausible Explanation for Obesity.
  Sanmiguel C, Gupta A, Mayer EA. Sanmiguel C, et al. Curr Obes Rep. 2015 Jun;4(2):250-61. doi: 10.1007/s13679-015-0152-0. Curr Obes Rep. 2015. PMID: 26029487 Free PMC article. Review.
• Hepatic lipid-associated macrophages mediate the beneficial effects of bariatric surgery against MASH.
  Revelo X, Fredrickson G, Florczak K, Barrow F, Dietsche K, Wang H, Parthiban P, Almutlaq R, Adeyi O, Herman A, Bartolomucci A, Staley C, Jahansouz C, Williams J, Mashek D, Ikramuddin S. Revelo X, et al. Res Sq [Preprint]. 2023 Nov 2:rs.3.rs-3446960. doi: 10.21203/rs.3.rs-3446960/v1. Res Sq. 2023. PMID: 37961666 Free PMC article. Updated. Preprint.
• Obesity and appetite control.
  Suzuki K, Jayasena CN, Bloom SR. Suzuki K, et al. Exp Diabetes Res. 2012;2012:824305. doi: 10.1155/2012/824305. Epub 2012 Aug 1. Exp Diabetes Res. 2012. PMID: 22899902 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program